BDBM135817 US10085990, Example 84::US10568888, Example 84::US8853226, 84::US9393245, 84::US9833457, 84
SMILES COc1cccc2c1ncc1c2n(C2CCCC2)c(=O)n(-c2ccc3OCOc3c2)c1=O
InChI Key InChIKey=JMKXHWHMULJLQG-UHFFFAOYSA-N
Data 12 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 12 hits for monomerid = 135817
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
High Point Pharmaceuticals
US Patent
High Point Pharmaceuticals
US Patent
Affinity DataIC50: 513nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from "Molecular Devices" was used to test whether these compounds were indeed direct inhibitors of the PD...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
High Point Pharmaceuticals
US Patent
High Point Pharmaceuticals
US Patent
Affinity DataIC50: 827nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from "Molecular Devices" was used to test whether these compounds were indeed direct inhibitors of the PD...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMT: 2°CAssay Description:Add 100 μL of sample or standards in Reagent Diluent, or an appropriate diluent, per well. Cover with an adhesive strip and incubate 2 hours at ro...More data for this Ligand-Target Pair
TargetIsoform PDE4B2 of cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B2)(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 513nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffe...More data for this Ligand-Target Pair
TargetIsoform 10 of cAMP-specific 3',5'-cyclic phosphodiesterase 4D (10)(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 827nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffe...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
High Point Pharmaceuticals
US Patent
High Point Pharmaceuticals
US Patent
Affinity DataIC50: 827nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
High Point Pharmaceuticals
US Patent
High Point Pharmaceuticals
US Patent
Affinity DataIC50: 513nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
High Point Pharmaceuticals
US Patent
High Point Pharmaceuticals
US Patent
Affinity DataIC50: 827nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetIsoform PDE4B2 of cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B2)(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 513nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from Molecular Devices was used to test whether these compounds were indeed direct inhibitors of the PDE4...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
High Point Pharmaceuticals
US Patent
High Point Pharmaceuticals
US Patent
Affinity DataIC50: 827nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from Molecular Devices was used to test whether these compounds were indeed direct inhibitors of the PDE4...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
High Point Pharmaceuticals
US Patent
High Point Pharmaceuticals
US Patent
Affinity DataIC50: 513nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair